ABBV vs MMSI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
MMSI presents a dichotomy between strong fundamental growth and poor market sentiment. While the Piotroski F-Score of 4/9 indicates stable but not strong financial health, the company boasts an exceptional track record of earnings beats over 25 quarters and strong YoY earnings growth of 38.8%. However, the stock is currently trading at $70.54, which is a premium to its Intrinsic Value ($62.83) and significantly above its Graham Number ($35.75). Bearish insider activity and a 0/100 technical trend offset the bullish analyst target of $101.18.
Compare Another Pair
Related Comparisons
ABBV vs MMSI: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and Merit Medical Systems, Inc. (MMSI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.